Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-cycle adjuvant BEP in high‑risk stage I non-seminomatous testicular cancer
2008-006295-29Phase 4Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bleomycin, etoposide and cisplatin in Germ Cell Testicular Cancer and mixed germ cell testicular cancer (MGCTT), sponsored by The Institute of Cancer Research. Primary endpoints: 2-year recurrence rate and Safety and tolerability. Status: unknown.
02
Drugs
bleomycinetoposidecisplatin
03
Conditions
Germ Cell Testicular Cancermixed germ cell testicular cancer (MGCTT)
Beyond the preview
Go deeper on 2008-006295-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006295-29.